Module

Current Hormonal Therapy Strategies for Estrogen Receptor–Positive Postmenopausal Breast Cancer

Source: Management of ER+ Postmenopausal Early Breast Cancer

Current Hormonal Therapy Strategies for Estrogen Receptor–Positive Postmenopausal Breast Cancer

Program Director: Paul E. Goss, MD, PhD, FRCPC, FRCP

Faculty:
Ruth O'Regan, MD

CME CREDIT INFORMATION

Release Date: 05/09/08

Expiration Date: 05/08/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe current hormonal treatment strategies for ER-positive postmenopausal breast cancer patients
Discuss the mechanism of action of aromatase inhibitors
Cite clinical trial efficacy data supporting the use of tamoxifen or aromatase inhibitors in ER-positive postmenopausal early-stage breast cancer patients

Topics covered include:

Introduction
ATAC Trial: Anastrozole vs Tamoxifen
BIG 1-98: Letrozole vs Tamoxifen
IES: Tamoxifen vs Tamoxifen Followed By Exemestane
Anastrozole Sequencing Studies
MA.17: Tamoxifen Followed by Letrozole or Placebo
Summary

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.